COMP <GO>
SBFM vs APVO // EV/EBITDA & P/E VALUATION
Sunshine Biopharma Inc. (NASDAQ) VS. Aptevo Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SBFM 4
— APVO 0
■ METRIC PARITY
LAST: $3.33 (+7.07%) • MKT CAP: $2.5M
valuation
—
LAST: $1.36 (+4.62%) • MKT CAP: $2.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SBFM VS. APVO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SBFM | APVO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.40% | -35.00% | +13.60 | SBFM | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -17.20% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -16.50% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 4.10% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 2/9 | +2.00 | SBFM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.3 | 26.9 | +0.45 | SBFM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.5M | $2.5M | $83.4K | SBFM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SBFM REV | APVO REV | SBFM GROSS % | APVO GROSS % | SBFM FCF | APVO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $36.3M | $0 | 33.8% | — | -$5.5M | -$25.6M |
| FY 2024 | $34.9M | $0 | 30.6% | — | -$14.2M | -$23.8M |
| FY 2023 | $24.1M | $0 | — | — | -$8.8M | -$11.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SBFM // BETA —
APVO // BETA —